Compare Neurocrine Biosciences Inc (NBIX) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while ABRDN Physical Gold Shares ETF trades at $41.8. Which is the better fit depends on your goals.
| NBIX | SGOL | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $185.50 | $51.41 |
52-Week Low | $123.10 | $34.68 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SGOL is trading at $41.48, down 1.78% with a bearish technical outlook as moving averages signal selling pressure. The stock faces resistance at $42 with support at $41, while RSI indicators show mixed signals. Recent news highlights institutional optimism for gold's medium-term prospects despite near-term volatility, with Goldman Sachs forecasting $4,900/oz gold by year-end.
The outlook remains cautiously optimistic as gold benefits from macroeconomic support including debt concerns and central bank demand. Key risks include Fed policy uncertainty and dollar strength, while technical weakness suggests potential for further consolidation before sustained upward movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
